#185 | GLP-1: Microdosing? | Vyvyane Loh MD

Professional Supplements for Wise Athletes (click to see the huge "always on" discount)

Vyvyane Loh MD

• Board certified in internal medicine and obesity medicine, with a long focus on immunometabolism.
• Her book, The Architecture of Enough: Hunger, GLP-1, and the Immune Metabolic System, is available on Amazon (paperback: https://www.amazon.com/Architecture-Enough-Hunger-Immune-Metabolic/dp/B0H2R8HKS4 — and Kindle) and Barnes & Noble.
• She also publishes an in-depth health e-zine at wellth-e.com (WELLTH-E — "wealth" as in money plus wellness); she points listeners to issue #3

Bottom line: For an otherwise healthy, fit person chasing a modest amount of weight, Dr. Loh's take is stay away if you can — the muscle and immune-metabolic costs outweigh the benefit, and these drugs are best reserved for clear medical need, used with a real clinician and a defined exit strategy.

*Note: Educational, not medical advice. Dr. Loh stresses these decisions should be made with a clinician genuinely involved in your care.*

Key learnings

1. Ask "where's the receptor?" to tell a direct drug effect from a general weight-loss effect.
2. Metabolism and immunity are inseparable — every metabolic change is an immune change.
3. Insulin resistance is an adaptive response; acute is healthy, chronic is the problem.
4. The drug delivers GLP-1 alone and supraphysiologically — missing the natural hormone "family" and overriding your own system.
5. GLP-1 curbs appetite partly by inducing a low-grade "sickness" state via IL-6.
6. IL-6 isn't just "bad"; suppressing it long-term may drive muscle loss and impair repair.
7. Biggest risk for fit people: trading fat for lost muscle (obesity+diabetes → sarcopenia+diabetes).
8. ~75% regain most weight within a year of stopping, even while keeping good diet habits.
9. Beware catabolic states — surgery, illness, immobility — while on these drugs.
10. Skip no-follow-up, online platforms; pair any GLP-1 use with real lifestyle structure (meals, protein, hydration, sleep, lifting).

Summary

• Two years after her last appearance, Dr. Vyvyane Loh returns to tackle the drugs everyone's asking about — the GLP-1s (Ozempic, Wegovy, semaglutide). Joe comes in tempted, like a lot of listeners: not a hundred pounds to lose, just a stubborn ten and the promise that these drugs are also good for your heart, kidneys, liver, and longevity. Dr. Loh's job in this episode is to separate what's real from what's hype — and to explain what these drugs may be costing that the marketing never mentions.
• Her first tool for cutting through the noise is a simple question: "where is the GLP-1 receptor?" If a supposed benefit is happening in a tissue that has no GLP-1 receptor, it's probably just a general effect of losing weight (better sleep apnea, less inflammation) — not a direct, magical property of the drug. Much of the "good for everything" story, she argues, is really just "weight loss is good for people who were carrying excess fat."
• The conceptual heart of the episode is her core thesis: metabolism and the immune system are the same conversation. Any metabolic intervention is also an immune intervention, and vice versa. She reframes insulin resistance not as a villain but as a natural, adaptive response — during infection, inflammation, or pregnancy, the body deliberately becomes insulin resistant so glucose spills into the bloodstream to fuel immune cells, the liver, and the brain. Acute insulin resistance is good design; it's *chronic* insulin resistance, driven by poor sleep, junk food, and constant stress, that turns destructive and can progress to diabetes.
• On the mechanics: GLP-1 isn't just a "gut hormone." It's made in the gut, brain, and pancreas, and your own natural version has a half-life of about two and a half minutes. More importantly, your body makes GLP-1 by chopping up a big parent molecule (proglucagon) into a whole family of hormones — GLP-1, GLP-2, oxyntomodulin, glicentin — in balanced proportions that work together. The drugs "slam" just GLP-1 on board, in a modified form that resists breakdown and persists for weeks, at a bioavailable level Dr. Loh estimates is roughly 40–70× your natural peak. So the common "it's just natural GLP-1" pitch is, in her words, not really accurate — it's a supraphysiologic dose that overrides your own system.
• Then the twist. GLP-1 is tightly linked to IL-6, an inflammatory cytokine, and to "sickness behavior." Inflammation raises GLP-1, and GLP-1 in turn drives IL-6 in immune cells — producing exactly the state you feel when you're sick: no appetite, low energy, low motivation. In a real sense, Dr. Loh explains, part of how GLP-1 curbs eating is by "making the body think it's mildly sick". And IL-6 isn't simply "bad" — it has multiple "voices," including a homeostatic one that's essential for muscle growth after exercise, brain development, and tissue repair after a stroke or concussion. Chronic GLP-1 use suppresses IL-6 overall, shifting your immune tone — one likely reason it's so hard to hold onto muscle on these drugs.
• That muscle concern drives her caution for this audience. Her worry isn't the person with 100 pounds to lose; it's the fit, healthy person chasing eight to ten pounds and risking their muscle mass to do it. She paints the long-game picture: start at 55 with obesity and diabetes, and ten years of "stay on it forever" can leave you at 65 with sarcopenia and diabetes. A "microdose," she notes, is still supraphysiologic — and for small weight loss, not meaningfully different from a cheap old appetite suppressant like phentermine. Meanwhile, roughly "75% of people regain most of the weight within a year of stopping" — even those who kept their good habits — because the underlying biology reasserts itself.
• She's careful not to be absolutist: some people genuinely benefit. But she insists on knowing *why* someone is on the drug, what success looks like, and what the exit strategy is. And she flags real risks around catabolic states — surgery, illness, injury, even long sedentary travel — where being on a GLP-1 can impair wound healing (surgeons and anesthesiologists are increasingly wary, also citing gastroparesis and aspiration risk).
• If someone is still going to try, her practical guardrails: DO NOT use the click-a-button telehealth or gym platforms with no real follow-up (your poor primary care doctor ends up cleaning up the mess); work with a clinician actually involved in your care; and remember that "every pivotal trial paired the drug with intensive lifestyle support" — weekly dietitian and coaching visits for 72 weeks. Build the structure first: scheduled meals, adequate protein, hydration, sleep, and resistance training. The drug was never meant to replace the work, and "eat whatever you want" is marketing, not medicine.

Related Episodes & Links:

• Episode 137 | The #1 Secret to Healthy Fat Loss | Vyvyane Loh MD
• Episode 135 | What's Your Healthy Bodyfat %? | Vyvyane Loh MD
• Episode 183 | VO2Max or What? | Mike T Nelson, PhD
• Episode 182 | Leveraging Energy Stress | Jose Areta, PhD

Help the show:

3 ways to support our show: 

• Leave a review (or share this episode)
• Check out our Fullscript site to save big on high quality supplements. Thank you!
• Email us your questions at [email protected].